ArticleOncoTargets and therapy2020
Mannose Suppresses the Proliferation and Metastasis of Lung Cancer by Targeting the ERK/GSK-3β/β-Catenin/SNAIL Axis.
Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- Collateral Impact of Mannose Supplementation on Metastatic Properties in Osteosarcoma Cell Models.Biology · 2026Article
- Unravelling the role of tumor microenvironment responsive nanobiomaterials in spatiotemporal controlled drug delivery for lung cancer therapy.Drug delivery and translational research · 2025Review
- D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC.Oncogene · 2023Article
- ANP32A Knockdown Attenuates the Malignant Biological Behavior of Colorectal Cancer Cells by Suppressing Epithelial-mesenchymal Transition and ERK Activation.Journal of Cancer · 2023Article
- Echinacoside Induces Mitochondria-Mediated Pyroptosis through Raf/MEK/ERK Signaling in Non-Small Cell Lung Cancer Cells.Journal of immunology research · 2022Article
- Mannose: A Sweet Option in the Treatment of Cancer and Inflammation.Frontiers in pharmacology · 2022Review
- Mannose inhibits the growth of prostate cancer through a mitochondrial mechanism.Asian journal of andrologyArticle
Corrections and comments
- Retraction · 2024-01-25Author Unresponsive · Concerns/Issues about Image · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Investigation by Third Party · Paper Mill · Plagiarism of Image · Unreliable Results and/or Conclusions · · see also: https://pubpeer.com/publications/48A6C2076FFF94DCF511F47B6E2F49
- Retracted
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIt has been found that mannose exerts antitumoural properties in vitro and in animal models. Whether mannose has potential anti-proliferative and anti-metastatic properties against non-small-cell lung cancer (NSCLC) is still unclear.
methodsHere, we performed ex vivo experiments and established a nude mouse model to evaluate the anticancer effects of mannose on NSCLC cells and its effects on the ERK/GSK-3β/β-catenin/SNAIL axis. A CCK-8 assay was conducted to evaluate the effects of mannose on lung cancer cells (A549 and HCC827) and normal lung cells (HPAEpiC). Transwells were used to examine the motility of cancer cells. qRT-PCR was used to evaluate the effects of mannose on the mRNA expression of β-catenin. Western blotting was conducted to explore the effects of mannose on the ERK/GSK-3β/β-catenin/SNAIL axis and nuclear accumulation of β-catenin. An animal model was established to evaluate the antitumoural effect of mannose on hepatic metastasis in vivo.
resultsIn this study, we found that mannose inhibited the proliferation of A549 and HCC827 cells in vitro both time- and dose-dependently. However, it exerted only a slight influence on the viability of normal lung cells in vitro. Moreover, mannose also inhibited the migrating and invading capacity of NSCLC cells in vitro. Using Western blotting, we observed that mannose reduced SNAIL and β-catenin expression and ERK activation and promoted phospho-GSK-3β expression. The ERK agonist LM22B-10 promoted the metastatic ability of NSCLC cells and increased SNAIL and β-catenin expression in cancer cells, which could be reversed by mannose. Furthermore, ERK-mediated phosphorylation of the β-catenin-Tyr654 residue might participate in the nuclear accumulation of β-catenin and its transcriptional function. The results from animal experiments showed that mannose effectively reduced hepatic metastasis of A549 cells in vivo. Furthermore, mannose inhibited ERK/GSK-3β/β-catenin/SNAIL in tumour tissues obtained from nude mice. DISCUSSION: Collectively, these findings suggest that mannose exerts anti-metastatic activity against NSCLC by inhibiting the activation of the ERK/GSK-3β/β-catenin/SNAIL axis, which indicates the potential anticancer effects of mannose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.